Q Therapeutics of the United States and REPROCELL of Japan are teaming up to develop stem cell-based therapies for central nervous system diseases such as ALS and transverse myelitis, or TM. The collaboration will meld Q Therapeutics’ expertise in nerve cell therapy with REPROCELL’s expertise in stem cell treatments.
Q Therapeutics and REPROCELL Partnering on Stem Cell-based Therapies for ALS
Patients with amyotrophic lateral sclerosis (ALS) experience a gradual loss of the ability to walk, swallow and even breathe, and there’s no cure. It’s incredibly important that patients seek specialized treatment to address the different aspects of the disease. MORE: Find out seven ways to diagnose ALS In…
A group of women in their 60s decided to go full Monty to raise awareness for amyotrophic lateral sclerosis (ALS). The idea came from lifelong friends of Wendy Rauwerdink of Sheboygan, Wisconsin, who had diagnosed with the disease. Her friends became engaged in the fight, always wanting to do more. As…
Two young companies, QurAlis and Kernal Biologics, are winners of the Amgen Golden Tickets for innovative bioscience projects — in this case, work that might lead to better treatments in amyotrophic lateral sclerosis (ALS) and cancer immunotherapy, Amgen and LabCentral announced. QurAlis is developing therapies for three different forms of…
Social Clips
Neurologist Talks About Diagnosing ALS
In this video from the Brattleboro Reformer, learn more about how ALS patients like Andy are diagnosed from a doctor’s point of view. MORE: Andy shares his ALS journey in this touching video Neurologist Dr. Elijah Stommel explains that he sees two newly diagnosed ALS patients each week and that each…
With 2017 quickly coming to a close, I decided to learn a little more about my readers and which of my posts were the most popular. While scrolling through the numbers I identified my most-read posts and the posts that drew the most comments. I learned that ultimately, we…
The Wave Life Sciences therapy WVE-3972-01 reduced markers of the form of ALS that scientists believe stems from a gene mutation, studies show. Researchers said the potential treatment blocked faulty versions of messenger RNA associated with the production of abnormal C9orf72 protein. The RNA is an intermediary between the C9orf72 gene…
MediciNova announced successful top-line results from a Phase 2 clinical trial of MN-166 (ibudilast) as an adjunct therapy to Rilutek (riluzole) in patients with amyotrophic lateral sclerosis (ALS). The treatment was safe and well-tolerated – meeting the trial’s primary endpoint – and was found to be more effective at…
Ludwig Cancer Research scientist Don Cleveland has received a $3 million Breakthrough Prize for increasing science’s understanding of how an inherited form of amyotrophic lateral sclerosis develops. His work focused on glia, cells that support the body’s production of a protein called myelin, which protects nerve cells. Deterioration of myelin…
Social Clips
Surfers Unite to Fight Against Motor Neuron Disease
https://vimeo.com/147387124 In 2015, the Cure for MND Foundation visited the RipCurl Pro Bells Beach in Australia and chatted with some of the world’s top surfers about the best waves, worst wipeouts and a somewhat surprising topic: motor neuron disease. MORE: Find out more about a group of ladies…
Recent Posts
- I reframed my life with ALS by becoming a calmer duck
- New ALS treatment improves survival, leads to function gains in trial
- ALS Network, ALS United calling for ‘bold’ research proposals for funding
- Study finds common medications that could be repurposed to treat ALS
- New eye imaging approach may help distinguish ALS from Alzheimer’s